Cytori to Develop Cell-Based Treatments for Vascular Disease
Posted on: Friday, 21 September 2007, 12:00 CDT
Cytori Therapeutics has been awarded a $250,000 National Institutes of Health grant to develop adipose-derived regenerative cells as a treatment for vascular disease.
The grant work will study adipose-derived regenerative cells in preclinical vascular disease models. This will involve looking into which cells within adipose tissue are optimal for remodeling and promoting growth of both small and larger blood vessels. In addition, the research will explore the capacity of adipose-derived regenerative cells in patients with a history of smoking, hypertension, and diabetes.
Marc Hedrick, president, Cytori Therapeutics, said: "This grant allows Cytori to expand the number of therapeutic applications for adipose-derived regenerative cells. Due to the shared mechanism of these cells in vascular and heart disease, this research will complement and provide valuable insight into our clinical-stage development of treatments for cardiovascular disease."
John Fraser, principal scientist, Cytori Therapeutics, said: "We look forward to this grant building on the success of our earlier NIH grant. That research led to the clinical trials we are now performing in cardiovascular disease. Successful completion of the new grant may potentially qualify us for additional funding at a higher level that we believe will lead to similar clinical opportunities in other disease states."
Source: Datamonitor
Related Articles
- New Type Of Immune Cells Regulating Inflammation In Chronic Diseases: Th22 Cells As Milestone Of Immunological Research
- Pitt Researchers To Explore Better Ways To Grow Cells For Regenerative Medicine
- Hard To Treat Diseases (HTDS.PK) Stem Cells and Regenerative Medicine
- Stem Cells in Regenerative Medicine 2008 Market Report Focuses on the Various Clinical Applications of Different Types of Stem Cells
- 21Ventures and the Quercus Trust Award $200,000 Grant to Support the Solar Energy Research of Professor David Cahen of the Weizmann Institute of Science
- Gamma Secretase Modulators Show Promise in Alzheimer's Disease Animal Model Efficacy Studies, According to Research Conducted By TorreyPines Therapeutics
- South Texas Accelerated Research Therapeutics Gains Highly Respected Cancer Drug Researcher Michael Wick, Ph.D.
- Renowned Cancer Drug Researcher Chris Takimoto, M.D., Ph.D., Joins South Texas Accelerated Research Therapeutics
- Cytori Therapeutics Presents at Cell-Based Regenerative Medicine Symposium
- Using Pluripotent Germ Cells in Regenerative Medicine: An Ethical Alternative
 |
 |
User Comments (0)
RSS Feeds